Regeneron Investor Interest

Order byBest matchMost fresh

Regeneron to buy bankrupt DNA testing company 23andMe

Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data

Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of customers' DNA data.

· 19h · on MSN

Bankrupt DNA testing company 23andMe to be acquired by Regeneron for $256 million

· 1d

Regeneron agrees to buy bankrupt 23andMe

· 1d

Struggling DNA testing firm 23andMe to be bought for $256m

23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m (£192m).

· 1d

23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction

· 1d

Bankrupt DNA testing company 23andMe to be bought by Regeneron

Rolling Out1d

The fall of 23andMe and what it means for your DNA

The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.

1don MSN

Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly handed over the samples to completely different owners.

Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down

Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% rise in 3 years.

23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.

Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles including a data breach.

Morningstar29d

Regeneron Announces Investor Conference Presentations

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...

STAT4d

Amgen loses $400 million antitrust battle to Regeneron

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron more than $400 million now, and more.

Fintel on MSN6d

Citigroup Upgrades Regeneron Pharmaceuticals (REGN)

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from Neutral to Buy. Analyst Price Forecast Suggests 44.26% Upside As of May 6, 2025,

4don MSN

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha over rival's Praluent. Read more here.